March 31, 2014

The Food and Drug Administration on Friday approved over-the-counter Nexium 24HR (esomeprazole 20mg), Pfizer announced.

March 20, 2014

AstraZeneca on Wednesday launched Nexium Direct, a program that provides eligible patients the option of having brand-name Nexium delivered directly to their home.

December 26, 2013

Heading into 2014, there are a number of growth drivers across the digestives space.

May 8, 2013

There is as much as $10 billion in branded pharmaceutical sales that could make the switch from prescription-only to over-the counter in the next five years, suggested Joseph Papa, Perrigo chairman, CEO and president, to analysts on Tuesday.

November 8, 2012

Business for OTC store brands is expected to boom in the coming year, Perrigo chairman and CEO Joseph Papa told analysts discussing the private-label manufacturer's first quarter results during a conference call Wednesday, even as the growth rate across the entire OTC category slows.

August 17, 2012

Procter & Gamble’s Prilosec OTC still is the best-selling antacid on the market, with more than $252.7 million in annual sales for the 52 weeks ended July 8 across food, drug and mass (excluding Walmart), followed by fellow proton-pump inhibitor Novartis’ Prevacid 24HR ($104.1 million).


August 13, 2012

Pfizer will be the next consumer healthcare company to reach the market with a switched proton-pump inhibitor.

August 25, 2011

AstraZeneca is offering a discount savings program for its prescription acid reflux disease treatment.

August 9, 2011

Hetero is at the center of two patent litigation suits for attempting to market generic versions of Viagra and Nexium, according to published reports.

August 3, 2011

Topco, a member-owned cooperative serving the food industry, recently kicked off an initiative substituting its TopCare-branded over-the-counter medicines for the equivalent prescription pharmaceutical, where appropriate, in an effort to save patient dollars and promote the TopCare brand.

April 5, 2011

Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.